Medical disclaimer
Stem cell transplant for children with HLH: do gene mutations change outcomes?
8 min read
Prepared by Bookimed editorial team
Medical content and care coordination

The named clinic is an author affiliation. The study patients were not established as patients treated at that clinic.
Key takeaways
- The study followed 153 children with hemophagocytic lymphohistiocytosis (HLH) who had a donor stem cell transplant.
- Children were split into four groups by gene finding: PRF1 (46), UNC13D (38), STX11/STXBP2 (25) and Griscelli syndrome type 2 or Chediak-Higashi syndrome (44).
- The abstract reports no difference between the groups in engraftment, graft and survival measures, and complication rates.
- Remission status before transplant was the most important factor for survival in all groups.
- These are group results from past patients and are not a forecast for any one child.
The question this study addresses
The authors looked back at records of children with primary HLH who had an allogeneic hematopoietic stem cell transplant (allo-HSCT, a transplant using donor cells). They asked whether the gene mutation changes results. They compared engraftment (donor cells taking hold), veno-occlusive disease (VOD, a liver blood vessel complication), acute and chronic graft-versus-host disease (GVHD, donor cells attacking the body), transplant-related mortality (TRM), overall survival (OS) and event-free survival (EFS). Patients came from 18 paediatric stem cell centres in Turkey. Authors 1, 5 and 11 list the Pediatric BMT Unit at Medical Park Göztepe Hospital, Istanbul, as their affiliation. The abstract does not say which patients were treated there.
- The situation
- Children with primary HLH, grouped by PRF1, UNC13D, STX11/STXBP2 mutation, or a diagnosis of Griscelli syndrome type 2 or Chediak-Higashi syndrome.
- The treatment
- Allogeneic hematopoietic stem cell transplant (allo-HSCT).
What this evidence cannot establish
- Medical Park Göztepe Hospital Complex appears as an author affiliation; the patients came from 18 centres, and the abstract does not say that they were treated at this clinic.
- The study looked back at past records, so it cannot show that a gene group caused any difference.
- The abstract gives numbers only for 5-year event-free survival, not for the other measures.
Patient groups in the published study
46 patients · Published study group
Children with PRF1 mutation HLH
- Indication
- Primary HLH with a PRF1 mutation
- Treatment
- Allogeneic stem cell transplant
46 children
Children with primary HLH and a PRF1 mutation who had a donor stem cell transplant at one of the participating centres.
Allogeneic hematopoietic stem cell transplant. The abstract does not give details of the donor type or conditioning.
5-year event-free survival
71%
46 patients · Study group
5 years
Limits of this evidence
- The abstract gives no numbers for survival, GVHD, VOD or TRM in this group alone.
For a clinic assessment
- Genetic test report showing the mutation
- Transplant and remission status records
38 patients · Published study group
Children with UNC13D mutation HLH
- Indication
- Primary HLH with a UNC13D mutation
- Treatment
- Allogeneic stem cell transplant
38 children
Children with primary HLH and a UNC13D mutation who had a donor stem cell transplant at one of the participating centres.
Allogeneic hematopoietic stem cell transplant. The abstract does not give details of the donor type or conditioning.
5-year event-free survival
66.6%
38 patients · Study group
5 years
Limits of this evidence
- The abstract gives no numbers for survival, GVHD, VOD or TRM in this group alone.
For a clinic assessment
- Genetic test report showing the mutation
- Records of disease status before transplant
25 patients · Published study group
Children with STX11/STXBP2 mutation HLH
- Indication
- Primary HLH with an STX11 or STXBP2 mutation
- Treatment
- Allogeneic stem cell transplant
25 children
Children with primary HLH and an STX11 or STXBP2 mutation who had a donor stem cell transplant at one of the participating centres.
Allogeneic hematopoietic stem cell transplant. The abstract does not give details of the donor type or conditioning.
5-year event-free survival
74%
25 patients · Study group
5 years
Limits of this evidence
- This was the smallest group, so its result is less certain than a larger group's.
- The abstract gives no numbers for survival, GVHD, VOD or TRM in this group alone.
For a clinic assessment
- Genetic test report showing the mutation
- Records of disease status before transplant
44 patients · Published study group
Children with Griscelli syndrome type 2 or Chediak-Higashi syndrome
- Indication
- Griscelli syndrome type 2 (GS2) or Chediak-Higashi syndrome (CHS) with HLH
- Treatment
- Allogeneic stem cell transplant
44 children
Children diagnosed with GS2 or CHS and HLH who had a donor stem cell transplant at one of the participating centres.
Allogeneic hematopoietic stem cell transplant. The abstract does not give details of the donor type or conditioning.
5-year event-free survival
66.7%
44 patients · Study group
5 years
Limits of this evidence
- This group was defined by diagnosis, not by a single gene mutation like the other three.
- The abstract gives no numbers for survival, GVHD, VOD or TRM in this group alone.
For a clinic assessment
- Diagnosis report for GS2 or CHS
- Records of disease status before transplant
Results and limits of the study
The 5-year event-free survival was 71% for PRF1, 66.6% for UNC13D, 74% for STX11/STXBP2 and 66.7% for GS2/CHS. The authors report that the statistical test found no difference between the groups. They also report no difference in engraftment, VOD, acute GVHD, chronic GVHD, TRM, OS and EFS. Remission status before transplant was the most important factor for OS and EFS in all genetic groups. The authors say larger prospective studies with more detailed genetic analysis may find approaches specific to a genetic group.
Limitations and unknowns
- How many of the 153 children were treated at Medical Park Göztepe Hospital is not stated.
- Survival, GVHD, VOD and TRM rates per group are not given as numbers.
- The years of treatment and the follow-up beyond 5 years are not stated in the abstract.
- It is unclear whether results would differ for a child with other health problems.
What to clarify in your treatment plan
Before booking, ask the clinic whether it performs stem cell transplants for children with HLH and which team would care for your child. Ask what genetic and disease-status records it needs to review. Also ask who will coordinate follow-up care and how long the family may need to stay near the hospital.
Medical Park Göztepe Hospital Complex: clinic profile
- Authors 1, 5 and 11 list the Pediatric BMT Unit at Medical Park Göztepe Hospital, Istanbul, as their affiliation.
- The study used data from 18 paediatric stem cell centres, and the abstract does not say where each patient was treated.
- The clinic profile for Medical Park Göztepe Hospital Complex is available on Bookimed.

Medical Park Göztepe Hospital Complex
Istanbul, Turkey
4.4/5 · 35 Bookimed reviews (current clinic profile)
Safety and recovery: general information
General patient guidance, provided separately from the case evidence. Follow your treating team's instructions.
Possible side effects
- Bone marrow transplant complications may include anemia, bleeding, graft failure, infections that can be very serious, and damage to organs such as the kidneys, liver, lungs and heart.
Ask the transplant team which of these they watch for and how they would treat them.
- Graft-versus-host disease can occur when donor white blood cells see the body as foreign and attack it, which may damage the skin, liver, intestines and other organs.
Ask how the team checks for and manages GVHD.
- Long-term problems of stem cell transplants may include infertility, cataracts, new secondary cancers, organ damage, and bone and muscle weakness.
Ask about long-term follow-up for children after transplant.
Recovery and aftercare
- Recovery can take up to 1 year to be full, depending on what complications occur.
Ask the clinic what a typical follow-up schedule looks like.
- Even after blood counts return to normal, the immune system can take much longer to recover; for allogeneic transplants this may be 1 to 2 years.
Ask what precautions the clinic advises during this time.
Suitability and cautions
- Whether a transplant is right may depend on many factors, such as other treatments likely to work, donor availability, ability to tolerate high-dose chemotherapy and other serious health problems.
Only the treating transplant team can decide this for a child.
- In general, transplants may be more likely to be successful when done in remission and when overall health is good.
Ask how your child's remission status will be assessed.
When to contact the clinic
- A bone marrow transplant may cause symptoms such as chest pain, a drop in blood pressure, fever, chills, flushing, headache, hives, nausea, pain or shortness of breath.
Tell the care team at once if your child has any of these symptoms.
Request a personal plan from the clinic
Ask Medical Park Göztepe for a review of a child's HLH transplant records
Bookimed can send your child's records to the clinic for a case review and help arrange questions for the transplant team. Prices are not covered on this page.
Ask the clinic for a current, itemized quotation. Published evidence does not establish package inclusions or a current price.
Frequently asked questions
Who ran this study and where were the patients treated?
The study was a multicentre series using data from 18 paediatric stem cell centres in Turkey. Authors 1, 5 and 11 list the Pediatric BMT Unit at Medical Park Göztepe Hospital, Istanbul, as their affiliation. The abstract does not say how many patients were treated at that hospital, so the page does not claim that they were. Bookimed did not run or take part in the study.
Did the gene mutation change transplant results?
The abstract reports no difference between the four genetic groups in engraftment, VOD, acute and chronic GVHD, TRM, overall survival and event-free survival. The 5-year event-free survival values were 71%, 66.6%, 74% and 66.7%. The authors note that more detailed genetic work in future prospective studies may reveal differences.
What mattered most for survival in this study?
Remission status before transplant was the most important factor affecting overall and event-free survival in all genetic groups. This is a finding about past patients as a group. It does not predict what will happen for your child, and the transplant team must assess your child's own situation.
Does this study mean my child will have the same results?
No. The figures describe groups of children treated in the past and are not a forecast for any one child. Results can depend on remission status, overall health, donor availability and complications. Ask the transplant team how these apply to your child before making any decision.
Sources and scope
This page was prepared from the published abstract of the study, its listed author affiliations and general patient information from MedlinePlus, the National Cancer Institute and the American Cancer Society. Bookimed did not run the study.
- 1. Öztürk et al. – Effect of genetic mutations on outcomes of stem cell transplantation in children with hemophagocytic lymphohistiocytosis.
Retrospective multicentre series · 2025
153 children with HLH who had allogeneic stem cell transplant at 18 Turkish centres
Follow-up: 5-year event-free survival reported; other follow-up not stated in the abstract
Only the abstract was used, so details such as donor types, study years and per-group complication rates are not available.
- 2. MedlinePlus
- 3. National Cancer Institute
- 4. American Cancer Society
- 5. Medical Park Göztepe Hospital Complex on Bookimed
Scope and limitations
- A research summary is not an individual medical recommendation.
- Group results describe the study participants, not a forecast for any one patient.
Related procedures
About the editorial team

Prepared by
Bookimed editorial teamMedical content and care coordination
Bookimed prepares evidence summaries from published medical sources and anonymized care records. The clinic and any doctors named on this page are identified separately in their own sections.